About

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company provides Diallertest Milk, a diagnostic product for the detection of cow’s milk protein allergy (CMPA) in children. Its products include Viaskin Peanut, an immunotherapy product for the treatment peanut allergies in children, adolescents, and adults; Viaskin Milk for the treatment of CMPA and milk-induced eosinophilic esophagitis (EoE); and Viaskin Egg, a development program for the treatment of hen’s egg allergy. The company also develops other earlier stage product development programs, which comprise house dust mites allergy, EoE, pertusiss boost vaccine, and birch pollen allergy. DBV Technologies S.A. was founded in 2002 and is based in Bagneux, France.